Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society.
Myelodysplastic syndromes (MDS) represent a heterogeneous group of haematological disorders characterized by ineffective haematopoiesis and an increased risk for leukemic transformation. In recent years several new therapeutics have emerged that have demonstrated to alter the natural course of the disease. This document summarizes the state of the art in diagnosis and treatment of this heterogeneous disease, as proposed by a group of expert haematologists in the field of MDS from the Belgian Haematological Society. Its main purpose is to guide clinicians in daily practice to treat patients with this disease, within the limitations of current reimbursement modalities in Belgium.
Iridium Cancer Network, AZ KLINA, Brasschaat, Belgium. stef.meers@klina.be
S
S
Meers
Dept of Haematology, Hospital Network Antwerp, Campus Stuivenberg, Antwerp, Belgium.
D
D
Breems
AZTurnhout, Belgium.
G
G
Bries
Dept of Haematology, University Hospitals Leuven, Belgium.
M
M
Delforge
UCL Mont-Godinne, Yvoir, Belgium.
C
C
Graux
Hopital de Jolimont, Belgium.
C
C
Ravoet
AZ St-Jan, Bruges, Belgium.
D
D
Selleslag
Dept of Haematology, Ghent University Hospital, Belgium.
L
L
Noens
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use; D002614:Chelating Agents / Q000627:therapeutic use*; D017707:Erythrocyte Transfusion; D006397:Hematinics / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007501:Iron; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000175:diagnosis / Q000628:therapy*; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D002614:Chelating Agents; D006397:Hematinics; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D013792:Thalidomide; D007501:Iron; D000077269:Lenalidomide; D001374:Azacitidine